Global Decentralised Clinical Trials Market Report 2026-2036 Market To Reach US$33.5Bn At 11.5% CAGR As AI, Remote Monitoring And Hybrid Models Transform Drug Development

(MENAFN- GlobeNewsWire - Nasdaq) Boost trial ROI with AI-enabled monitoring, hybrid patient-centric models, resilient sourcing, real-time data capture and regulatory-aligned digital platforms.

Dublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Decentralised Clinical Trials Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering.

The global decentralised clinical trials market is projected to grow from US$11.3bn in 2026 to US$33.5bn by 2036, at a CAGR of 11.5%. This near-tripling in market value reflects the expanding role of decentralised and hybrid models in mainstream clinical development.

Market growth is being driven by advances in digital health technology, increased adoption of patient-centric trial designs, and wider use of remote monitoring and real-time data capture. These capabilities can improve participant engagement, strengthen data quality, and increase operational efficiency. AI and advanced analytics are also enabling predictive monitoring, adaptive trial design, and faster decision-making across clinical programmes.

Trade, Policy and Supply Chain Dynamics

Global trade conditions, regulatory changes, and geopolitical developments are influencing the deployment and cost of decentralised clinical trial technologies. The market depends on connected medical devices, sensors, wearable devices, and digital infrastructure - creating exposure to tariffs, export controls, component availability, and regional regulatory differences.

• Cost and pricing pressure: Higher device, technology, and compliance costs are placing additional pressure on clinical trial budgets.
• Supply chain resilience: Sponsors, technology providers, and clinical research organisations are diversifying suppliers and strengthening digital infrastructure.
• Regulatory requirements: GDPR, HIPAA, evolving approval pathways, and national data policies continue to affect market access and trial execution.
• Competitive positioning: Providers combining digital innovation, scalable operations, and regulatory expertise are better positioned to secure market share.

Competitive Landscape and Company Intelligence

The decentralised clinical trials market includes established technology vendors, clinical research organisations, and specialist digital health platforms. Medable, Science 37, IQVIA, Parexel, and other leading companies are expanding their capabilities through platform development, strategic partnerships, and investment in hybrid and fully decentralised trial models.

Competitive differentiation is increasingly based on technology integration, data compliance, global operational reach, scalability, and support for patient-centric study designs. Emerging providers are also gaining traction by offering flexible platforms, digital agility, specialist expertise, and cost advantages.

The report evaluates market positioning and strategic developments among 4G Clinical, Advarra Inc., Clario, ICON PLC, IQVIA Inc., Medable, Inc., Oracle Corporation, Parexel International Corporation, Science 37, and Veeva Systems. Company profiles assess business operations, financial and market positioning, product and technology capabilities, and strategic outlook.

Report Scope and Market Segmentation

This decentralised clinical trials market report combines quantitative revenue forecasting with strategic analysis of technology, competition, regulation, policy, and supply chain conditions. It provides global, regional, and national forecasts through 2036, supported by segment-level modelling.

• By Study Design: Observational, Interventional, and Expanded Access
• By Indication: Oncology, Cardiovascular, Immunology, Respiratory, and Others
• By Technology: Telemedicine, Mobile Healthcare, Wearable Devices, Web-Based, and Others
• By End-user: Pharmaceutical & Biopharmaceutical Companies, Clinical Research Organisations, and Others

Geographic Market Coverage

• North America: U.S. and Canada
• Europe: Germany, France, UK, Italy, Spain, Russia, Poland, Belgium, Switzerland, Netherlands, and Rest of Europe
• Asia Pacific: Japan, China, India, Australia, South Korea, Singapore, Taiwan, New Zealand, Malaysia, and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina, Colombia, Chile, and Rest of Latin America
• Middle East & Africa: GCC, South Africa, Egypt, and Rest of Middle East & Africa

Key Questions Addressed

• What will the global decentralised clinical trials market be worth by 2036?
• Which technologies, therapeutic indications, study designs, and end-user segments will generate the strongest growth?
• Which regional and national markets will offer the most significant commercial opportunities?
• How will digital health platforms, AI, remote monitoring, and hybrid trial models influence market development?
• How will tariffs, regulation, data protection requirements, and supply chain pressures affect costs and deployment?
• Which companies are best positioned to compete as decentralised clinical development expands?

Bespoke Intelligence and Customisation

Visiongain provides tailored market intelligence and advisory support for organisations requiring analysis aligned with specific commercial, operational, or investment priorities. Available services include custom market segmentation and forecasting, competitive benchmarking, policy and regulatory impact assessment, supply chain and sourcing intelligence, and scenario modelling covering tariffs and geopolitical risk.

Strategic Value of the Report

Digital transformation, regulatory evolution, and changing clinical development models are reshaping the decentralised clinical trials market. This report enables pharmaceutical companies, biopharmaceutical companies, clinical research organisations, technology providers, investors, and other stakeholders to identify growth opportunities, assess competitive threats, manage regulatory and supply chain risk, and support evidence-based strategic planning through 2036.

Key Attributes:

Report Attribute	Details
No. of Pages	385
Forecast Period	2026 - 2036
Estimated Market Value (USD) in 2026	$11.3 Billion
Forecasted Market Value (USD) by 2036	$33.5 Billion
Compound Annual Growth Rate	11.5%
Regions Covered	Global

Companies Featured

• 4G Clinical
• Advarra Inc.
• Castor EDC
• Clario
• Clinical Ink, Inc.
• CLOUDZBY, INC.
• Dassault Systemes SE (Medidata Solutions, Inc.)
• Ergomed Group
• Florence Healthcare, Inc.
• ICON PLC
• IQVIA Inc.
• Kore Wireless Group Inc.
• Labcorp Drug Development
• Medable, Inc.
• Medrio Inc.
• Novo Health Holdings
• Oracle Corporation
• Parexel International Corporation
• ProPharma Group MIS Limited
• Science 37
• Signant Health
• Syneos Health
• TFS HealthScience
• Thermo Fischer Scientific
• Thread Research
• Veeva Systems
• Acrostar
• ADAMAS Consulting
• Amazon Bedrock
• Amazon Web Services Inc.
• ArtiQ, Inc.
• Avio S.p.A.
• Berlinger & Co. AG
• BioReference Health, LLC
• Biostar
• Boehringer Ingelheim
• CareMetx, Inc.
• Catalent
• Cerberus Capital Management
• Chugai Pharmaceutical Co., Ltd.
• Clario
• Clario Holdings, Inc.
• Clinical Ink
• Cogstate Ltd.
• C Tech, Inc.
• Emsere, Inc.
• Evolvics
• Fascicolo Sanitario Elettronico (FSE)
• Google
• Hawthorne Effect, Inc.
• IgniteData Ltd.
• iRhythm Technologies
• Jaguar Land Rover Limited
• Labcorp Drug Development
• Labshares, Inc.
• Medical Guardian
• Medsafe
• Microsoft
• Microsoft Inc.
• Mistral AI, Inc.
• Mobilise-D
• Mural Health Technologies
• NeuroRx, Inc.
• Noss Research Consulting, LLC
• Novartis
• NVIDIA Corporation
• Olink Holding AB
• Oncomatryx
• OpenAI, Inc.
• Ouro Medicines Inc.
• Palantir Technologies Inc.
• Panacea, Inc.
• Paradigm Health, Inc.
• Parexel
• PathAI, Inc.
• PBL Technology Ltd
• Pfizer
• PrimeVigilance Limited
• Providence
• QbD Group
• Radialogica AB
• SEQSTER Inc.
• SK Life Science, Inc.
• SPRIM PRO
• Tandem Diabetes Care, Inc.
• Tipalti, Inc.
• WCG Clinical, Inc.
• Weave Bio, Inc.
• Agencia Nacional de Vigilancia Sanitaria (ANVISA)
• Center for Drug Evaluation (CDE)
• Central Drugs Standard Control Organization (CDSCO)
• China National Medical Products Administration (NMPA)
• Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)
• Dutch Clinical Research Foundation (DCRF)
• Egyptian Drug Authority (EDA)
• European Medicines Agency (EMA)
• GEOVIA
• Health Sciences Authority (HSA), Singapore
• Indonesia Clinical Research Centre
• Instituto de Salud Publica (ISP)
• Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)
• Israel Ministry of Health
• Japanese Foundation for Cancer Research
• Japanese Society for Inherited Metabolic Diseases
• Korea Health Industry Development Institute (KHIDI)
• Kyushu University Hospital, Japan
• Malaysian Guideline for Application of Clinical Trial Import Licence (CTIL)
• Medicines and Healthcare products Regulatory Agency (MHRA), UK
• MICIN
• Ministry of Food and Drug Safety (MFDS), South Korea
• Ministry of Health (MOH), Malaysia
• Ministry of Health and Population, Egypt
• Ministry of Health, Labour and Welfare (MHLW), Japan
• National Cancer Center Hospital (NCCH)
• National Department of Health, South Africa
• National Pharmaceutical Regulatory Agency (NPRA)
• National Pharmaceutical Regulatory Agency (NPRA), Malaysia
• NEUCA
• NIHR (National Institute for Health and Care Research), UK
• Osaka Medical and Pharmaceutical University (OMPU)
• Peru National Institute of Health (INS)
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan
• Research Ethics Committees (CEPs)
• Saudi Food and Drug Authority (SFDA)
• Saudi National Institute of Health (Saudi NIH)
• SEHA virtual hospital
• South African Health Products Regulatory Authority (SAHPRA)
• START Center for Cancer Research
• Taiwan Alliance of Clinical Trial Centers (TACTC)
• Taiwan Food and Drug Administration (TFDA)
• Tufts Center for the Study of Drug Development
• Turkish Medicines and Medical Devices Agency (TITCK)
• U.S. FDA
• UAE MOHAP
• Unified State Health Information System (EGISZ), Russia
• University of Oxford NeuroMetrology Laboratory
• UZ Leuven
• World Health Organization (WHO)
• Wonju Severance Christian Hospital

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09102026004107003653ID1111782989